title: Presentation, management and outcome of 32 patients with pregnancy-associated breast cancer: a matched controlled study.
abstract: Pregnancy-associated breast cancer (PABC) is a rare and challenging problem. We sought to describe epidemiology, management and outcome of women in whom breast cancer was diagnosed during pregnancy or within one year after delivery. Thirty-two women with PABC were referred to two European Union oncology centers between 1995 and 2007, 16 during pregnancy and 16 within 1 year after delivery. Data concerning diagnosis, management, delivery and fetal and maternal outcome were recorded. A group of 32 patients (matched controls) presenting with nonpregnancy-associated breast cancer (non-PABC) was matched for age at diagnosis, tumor size and stage to each PABC patient. Differences in outcome between the PABC and non-PABC groups were then assessed. Histological features were similar in both groups, except that estrogen receptor-negative tumors were more common in the PABC group. Three patients received chemotherapy and two others underwent surgery during pregnancy, with no excess toxicity or severe maternal/fetal adverse effects. All children in the PABC group were healthy, except for one exposed to epirubicin in utero and born with rectal atresia. Overall survival was similar in PABC and non-PABC patients (p = 0.449). The subgroup of patients with breast cancer diagnosed within one year after delivery showed a shorter time to relapse than controls or patients with gestational cancer (p = 0.0178). PABC is a special situation, necessitating individualized, multi-disciplinary management. Prognosis is similar for women with nongestational cancer matched for age and stage though poorer outcome postpartum should be further investigated.
authors.affiliation: Department of Obstetrics and Gynecology, Second Medical Faculty, Charles University in Prague, 150 00, Prague, Czech Republic. mhalaska@centrum.cz
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Halaska
authors.forename: George
authors.initials: G
authors.lastname: Pentheroudakis
authors.forename: Pavel
authors.initials: P
authors.lastname: Strnad
authors.forename: Hana
authors.initials: H
authors.lastname: Stankusova
authors.forename: Jiri
authors.initials: J
authors.lastname: Chod
authors.forename: Helena
authors.initials: H
authors.lastname: Robova
authors.forename: Lubos
authors.initials: L
authors.lastname: Petruzelka
authors.forename: Lukas
authors.initials: L
authors.lastname: Rob
authors.forename: Nicholas
authors.initials: N
authors.lastname: Pavlidis
mesh_terms: D000028:Abortion, Induced / Q000706:statistics & numerical data; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D002585:Cesarean Section; D003131:Combined Modality Therapy; D018153:Czech Republic; D036861:Delivery, Obstetric; D005260:Female; D006115:Greece; D006801:Humans; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000175:diagnosis* / Q000401:mortality / Q000601:surgery / Q000628:therapy; D011644:Puerperal Disorders / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000628:therapy; D011878:Radiotherapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human